1. Home
  2. SCYX vs VNRX Comparison

SCYX vs VNRX Comparison

Compare SCYX & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

HOLD

Current Price

$0.78

Market Cap

32.6M

Sector

Health Care

ML Signal

HOLD

Logo VolitionRX Limited

VNRX

VolitionRX Limited

HOLD

Current Price

$0.20

Market Cap

35.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SCYX
VNRX
Founded
1999
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
32.6M
35.0M
IPO Year
2014
2012

Fundamental Metrics

Financial Performance
Metric
SCYX
VNRX
Price
$0.78
$0.20
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
4
Target Price
$3.00
$2.50
AVG Volume (30 Days)
366.8K
1.6M
Earning Date
01-01-0001
02-22-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
38.00
EPS
N/A
N/A
Revenue
$257,000.00
$1,233,511.00
Revenue This Year
$170.77
$60.84
Revenue Next Year
$286.38
$404.89
P/E Ratio
N/A
N/A
Revenue Growth
N/A
59.10
52 Week Low
$0.57
$0.18
52 Week High
$1.29
$0.94

Technical Indicators

Market Signals
Indicator
SCYX
VNRX
Relative Strength Index (RSI) 60.36 33.45
Support Level $0.75 $0.19
Resistance Level $0.85 $0.28
Average True Range (ATR) 0.06 0.02
MACD 0.00 -0.00
Stochastic Oscillator 76.07 15.05

Price Performance

Historical Comparison
SCYX
VNRX

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

About VNRX VolitionRX Limited

VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.

Share on Social Networks: